Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study.

Christian Veltmann David Duncker Michael DoeringSiva GummadiMichael RobertsonThomas WittlingerByron J ColleyChristian PeringsOrvar JonssonJohann BauersachsRobert SanchezLars Siegfried Maier

Published in: European heart journal (2024)

Continuous optimization of guideline-recommended medical therapy for at least 180 days in HFrEF is associated with additional LVEF improvement > 35%, allowing for better decision-making regarding preventive implantable cardioverter-defibrillator therapy.

Keyphrases

heart failure
decision making
left ventricular
healthcare
atrial fibrillation
stem cells
bone marrow